Cooke & Bieler LP Trims Stake in Johnson & Johnson $JNJ

Cooke & Bieler LP trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 10.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 583,536 shares of the company’s stock after selling 70,345 shares during the period. Cooke & Bieler LP’s holdings in Johnson & Johnson were worth $120,763,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC increased its holdings in shares of Johnson & Johnson by 14.0% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 19,465 shares of the company’s stock worth $4,028,000 after buying an additional 2,385 shares during the last quarter. Fisher Asset Management LLC grew its position in Johnson & Johnson by 5.0% in the fourth quarter. Fisher Asset Management LLC now owns 8,866,207 shares of the company’s stock worth $1,834,862,000 after acquiring an additional 419,799 shares in the last quarter. Choate Investment Advisors increased its stake in Johnson & Johnson by 2.6% in the fourth quarter. Choate Investment Advisors now owns 195,113 shares of the company’s stock valued at $40,379,000 after acquiring an additional 4,988 shares during the last quarter. Sandy Cove Advisors LLC raised its position in Johnson & Johnson by 2.1% during the fourth quarter. Sandy Cove Advisors LLC now owns 6,806 shares of the company’s stock valued at $1,408,000 after purchasing an additional 140 shares in the last quarter. Finally, Sectoral Asset Management Inc. lifted its stake in Johnson & Johnson by 32.7% during the fourth quarter. Sectoral Asset Management Inc. now owns 20,300 shares of the company’s stock worth $4,201,000 after purchasing an additional 5,000 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.1%

NYSE:JNJ opened at $234.67 on Tuesday. The firm has a market capitalization of $564.91 billion, a P/E ratio of 27.13, a P/E/G ratio of 2.29 and a beta of 0.27. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The company has a fifty day moving average of $233.87 and a 200 day moving average of $223.88.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson’s payout ratio is presently 60.12%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, April 24th. Raymond James Financial increased their price target on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 15th. Loop Capital set a $220.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, January 27th. Finally, Argus increased their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.